ClinicalTrials.gg
CompletedNCT04325321BHSUpdated Sep 29, 2026Results posted

The Broken Heart Study II (BHS-II)

An interventional study of Stress reactivity test in Takotsubo Cardiomyopathy, sponsored by The Miriam Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by The Miriam Hospital · Not applicable, Interventional, and Basic science

How we know

Updated Sep 29, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Takotsubo Cardiomyopathy with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Takotsubo Cardiomyopathy · United States.

Started
2020
the only one that year
No phase
6 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
The Miriam Hospital

Among the 11 studies in Takotsubo Cardiomyopathy with a site in United States, this one is the only one that started in 2020, is one of 6 with no phase, and was the 10th registered.

Takotsubo Cardiomyopathy

63 studies on the registry are indexed under Takotsubo Cardiomyopathy; 26 are open to participants now.

Browse Takotsubo Cardiomyopathy studies →

Open to participants now

3 of the 11 studies in Takotsubo Cardiomyopathy with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Takotsubo Cardiomyopathy studies recruiting now, 19 (83%) set no upper age limit and none (0%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Takotsubo Cardiomyopathy with a site in United States, or all of them as a file.
02

Study summary

The goals of this study are as follows:

  1. To rigorously establish and characterize heterogeneity in the pathophysiology of Takotsubo Syndrome (TS).
  2. To rigorously test the contribution of TS triggering events and mental stress responsiveness to 1-year prognosis after TS event.
Read the detailed description

Newly admitted patients with a validated diagnosis of Takotsubo Syndrome (TS; n=106) will be enrolled from 3 large medical centers in the Providence, Rhode Island area. Between 2 and 4 weeks after discharge, clinically stable patients will undergo an in-person comprehensive interview to identify the events proximal to the onset of TS symptoms, complete a battery of psychosocial questionnaires and undergo a validated laboratory stress protocol. Baseline and reactive changes in measures of autonomic nervous system activity (epinephrine and norepinephrine - primary outcome), and in the secondary outcomes of cardiac vagal control and left ventricular function (ejection fraction; regional and global longitudinal strain assessed with speckle tracking echocardiography) will be assessed. Echocardiographic evaluations will be repeated 12 months thereafter together with information on major adverse cerebrovascular events.

03

Conditions studied

  • Takotsubo Cardiomyopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=18
  • A new diagnosis of takotsubo syndrome fulfilling Mayo Clinic criteria
  • Ability to understand and speak English

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to give
  • Severe cognitive impairment
  • Uncontrolled hypertension
  • Acute psychosis
  • High suicidal risk
  • Pregnancy
  • Poor echocardiographic window
  • Conditions that would interfere with adherence to study requirements (e.g., ongoing alcohol or substance abuse)
  • If the participant is clinically unstable
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (actual)

Study arms

  • Other
    Stress reactivity

    Stress reactivity test

    Other: Stress reactivity test

Interventions

  • OtherStress reactivity test

    The protocol consists of Resting Baseline (BL), Emotion Recall (ER), followed by a Recovery Phase (RP). Heart rate and blood pressure are measured at baseline and then every 5 minutes during ER and RP. Resting Baseline (BL - 10 min). The participant is instructed to rest quietly. Emotion Recall (ER - 5-10 min). The participant is instructed to think about the incident associated with the onset of their cardiac event and bring to mind details of the incident. When the participants have the incident clearly in mind, they are instructed to relate the incident and their experience out loud; frequent questions to re-elicit the emotion are asked. Recovery Phase (RP - 20 min). Upon completion of RP, the catheter is removed and participants are de-instrumented. Blood samples for plasma catecholamines, assessments of heart rate variability, and echocardiograms are performed 10-min into BL, 10-min into ER, and 18 minutes into RP.

06

What researchers measure

Primary outcomes

  1. Mean Change (in pg/mL) in Plasma Epinephrine Levels

    Blood samples for plasma epinephrine are collected during the stress reactivity test, 10-min into Baseline, 10-min into Emotion Recall, and 18 minutes into Recovery Phase. Change will be calculated by subtracting Baseline epinephrine levels from Emotion Recall levels.

    Time frame: At baseline

  2. Mean Change (in pg/mL) in Plasma Norepinephrine Levels

    Blood samples for plasma norepinephrine are collected during the stress reactivity test, 10-min into Baseline, 10-min into Emotion Recall, and 18 minutes into Recovery. Change will be calculated by subtracting Baseline epinephrine levels from Emotion Recall norepinephrine levels.

    Time frame: At baseline

Secondary outcomes

  1. Change in High Frequency Power Heart Rate Variability (Hf-HRV) in Ln Msec

    High frequency power heart rate variability (hf-HRV) will be determined during the stress reactivity test by averaging high frequency values for 4-min segments within each phase (Baseline, Emotion Recall), and change will be calculated (Emotion Recall minus Baseline). Data will be collected using a Digital Holter ECG Recorder - 5 Lead, 2 Channel.

    Time frame: At baseline

  2. Mean Change in Global Longitudinal Strain (GLS)

    GLS will be assessed during the stress reactivity test using off-line analysis software (TomTec imaging systems) and calculated as the average left ventricular longitudinal strain across the segments obtained using apical two, three, and four-chamber views. Because myocardial contraction results in left ventricular shortening in systole, GLS is a negative value. Change will be calculated by subtracting Baseline GLS from Emotion Recall GLS.

    Time frame: Baseline

Other outcomes

  1. Proportion of Patients With Major Adverse Cardiac and Cerebrovascular Events

    Composite of death from any cause, recurrence of TS, stroke, transient ischemic attack, and myocardial infarction.

    Time frame: 12 months

07

Results

Posted Sep 29, 2026

Participant flow

Participants were consecutively recruited from three large medical centers in the Providence, RI area. Recruitment occurred from September 2, 2020 through February 12, 2025. Participants were identified through a reviews of electronic medical records (EMR) at using the ICD-10 code I51.81 Participants with a confirmed diagnosis of Takotsubo syndrome received a letter inviting them to participate in the study.

Participant flow — Overall Study
MilestoneStress Reactivity
Started66
Completed65
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryMean Change (in pg/mL) in Plasma Epinephrine Levels

Blood samples for plasma epinephrine are collected during the stress reactivity test, 10-min into Baseline, 10-min into Emotion Recall, and 18 minutes into Recovery Phase. Change will be calculated by subtracting Baseline epinephrine levels from Emotion Recall levels.

Time frame:
At baseline
Reported as:
Mean · pg/ml
Mean Change (in pg/mL) in Plasma Epinephrine Levels
pg/mlStress Reactivity
Mean Change (in pg/mL) in Plasma Epinephrine Levels11.3 ± 27.2
PrimaryMean Change (in pg/mL) in Plasma Norepinephrine Levels

Blood samples for plasma norepinephrine are collected during the stress reactivity test, 10-min into Baseline, 10-min into Emotion Recall, and 18 minutes into Recovery. Change will be calculated by subtracting Baseline epinephrine levels from Emotion Recall norepinephrine levels.

Time frame:
At baseline
Reported as:
Mean · pg/ml
Mean Change (in pg/mL) in Plasma Norepinephrine Levels
pg/mlStress Reactivity
Mean Change (in pg/mL) in Plasma Norepinephrine Levels64.4 ± 178.8
SecondaryChange in High Frequency Power Heart Rate Variability (Hf-HRV) in Ln Msec

High frequency power heart rate variability (hf-HRV) will be determined during the stress reactivity test by averaging high frequency values for 4-min segments within each phase (Baseline, Emotion Recall), and change will be calculated (Emotion Recall minus Baseline). Data will be collected using a Digital Holter ECG Recorder - 5 Lead, 2 Channel.

Time frame:
At baseline
Reported as:
Mean · Ln msec
Change in High Frequency Power Heart Rate Variability (Hf-HRV) in Ln Msec
Ln msecStress Reactivity
Change in High Frequency Power Heart Rate Variability (Hf-HRV) in Ln Msec-0.06 ± 1.2
SecondaryMean Change in Global Longitudinal Strain (GLS)

GLS will be assessed during the stress reactivity test using off-line analysis software (TomTec imaging systems) and calculated as the average left ventricular longitudinal strain across the segments obtained using apical two, three, and four-chamber views. Because myocardial contraction results in left ventricular shortening in systole, GLS is a negative value. Change will be calculated by subtracting Baseline GLS from Emotion Recall GLS.

Time frame:
Baseline
Reported as:
Mean · % LV shortening
Mean Change in Global Longitudinal Strain (GLS)
% LV shorteningStress Reactivity
Mean Change in Global Longitudinal Strain (GLS)-0.2 ± 2.2
Other pre-specifiedProportion of Patients With Major Adverse Cardiac and Cerebrovascular Events

Composite of death from any cause, recurrence of TS, stroke, transient ischemic attack, and myocardial infarction.

Time frame:
12 months
Reported as:
Count of participants · Participants
Proportion of Patients With Major Adverse Cardiac and Cerebrovascular Events
ParticipantsStress Reactivity
Proportion of Patients With Major Adverse Cardiac and Cerebrovascular Events2

Adverse events

Collected over from enrollment to end of follow-up (12 months since enrollment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stress Reactivity1/65 (1.5%)1/65 (1.5%)5/65 (7.7%)
Most frequent serious events
Most frequent serious events
EventStress Reactivity
Takotsubo Syndrome recurrenceCardiac disorders1/65
Most frequent other events
Most frequent other events
EventStress Reactivity
chest pain - non cardiac originCardiac disorders5/65

Baseline characteristics

1 participant withdrew from the study and was excluded from the analysis because of

Age, Continuous
Age, Continuous(Years)Stress Reactivity
Mean65.1 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Stress Reactivity
Female63
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Stress Reactivity
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White61
More than one race0
Unknown or Not Reported3
Education
Education(Participants)Stress Reactivity
less than high school diploma21
college or some college37
post-graduate7
08

Study locations

1 site
  • The Miriam Hospital
    Providence, Rhode Island 02906, United States
09

References and documents

Publications

  • Salmoirago-Blotcher E, Keirns NG, Ouaddi S, Tripolone J, Liu C, Breault C, Dettmer A. Chronic adrenocortical activity and onset of Takotsubo syndrome. Eur J Cardiovasc Nurs. 2026 Jul 28;25(5):1033-1040. doi: 10.1093/eurjcn/zvag023. PubMed 41562264 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data generated under the project will be shared as per National Institutes of Health (NIH) Grant Policy and Lifespan Institutional Review Board guidelines. De-identified research data will be made available in a timely manner once the main findings from the final research data set have been accepted for publication. Access to these data will be available for educational or research purposes. Data will be de-identified to avoid linkages to individual research participants and will be free of variables that could lead to deductive disclosure of the identity of individual subjects.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: De-identified research data will be made available once the main findings from the final research data set have been accepted for publication.

Access criteria: Researchers interested in obtaining the de-identified data and associated documentation (e.g. codebook) can make a request to the principal investigator. requestors will be asked to sign a data sharing agreement that includes conditions to 1) protect the identity of participants, 2) limit use of data for educational and research purposes, and 3) prevent transfer of data to other users, and 4) acknowledge the data source. The de-identified data will be shared using Excel or Statistical Package for the Social Sciences (SPSS) file formats.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Nov 2025, 62 months.

Results were first posted in Sep 2026, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2020
First posted
Mar 27, 2020
StartActual
Sep 2, 2020
Primary completionActual
Nov 11, 2025
CompletionActual
Feb 28, 2026
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 29, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedMean changeChange (in pg/mL) in plasma epinephrine levelsPlasma Epinephrine LevelsTime frame: Up to 4 weeks → At baseline
  • EditedMean changeChange (in pg/mL) in plasma norepinephrine levelsPlasma Norepinephrine LevelsTime frame: Up to 4 weeks → At baseline
Sep 29, 2026
Secondary outcomes
3 edited, 1 removed
What changed in the outcomes
  • EditedChange in high frequency power heart rate variabilityHigh Frequency Power Heart Rate Variability (hfHf-HRV) in Ln msec (square)MsecTime frame: Up to 4 weeks → At baseline
  • EditedAverageMean Change in Global Longitudinal Strain (GLS)Time frame: 12 months → Baseline
  • RemovedLeft ventricular ejection fraction (%)Time frame: 12 months
  • Editedother outcomeProportion of patients with major adverse cardiacPatients With Major Adverse Cardiac and cerebrovascular eventsCerebrovascular EventsTime frame: 12 months
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedMean changeChange (in pg/mL) in plasma epinephrine levelsPlasma Epinephrine LevelsTime frame: Up to 4 weeks → At baseline
    • EditedMean changeChange (in pg/mL) in plasma norepinephrine levelsPlasma Norepinephrine LevelsTime frame: Up to 4 weeks → At baseline
    Secondary outcomes 3 edited, 1 removed
    What changed in the outcomes
    • EditedChange in high frequency power heart rate variabilityHigh Frequency Power Heart Rate Variability (hfHf-HRV) in Ln msec (square)MsecTime frame: Up to 4 weeks → At baseline
    • EditedAverageMean Change in Global Longitudinal Strain (GLS)Time frame: 12 months → Baseline
    • RemovedLeft ventricular ejection fraction (%)Time frame: 12 months
    • Editedother outcomeProportion of patients with major adverse cardiacPatients With Major Adverse Cardiac and cerebrovascular eventsCerebrovascular EventsTime frame: 12 months
    + 3 other changes: verification date, references and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04325321
Responsible party
Elena Salmoirago-Blotcher (Senior Research Scientist, Associated Professor of Medicine, The Miriam Hospital) — Principal investigator
First posted
Mar 27, 2020
Start date
Sep 2, 2020
Primary completion
Nov 11, 2025
Completion
Feb 28, 2026
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Elena Salmoirago-Blotcher, MD, PhD
principal investigator · The Miriam Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion